ExpreS2ion Biotech Holding AB
STO:EXPRS2
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (28.7), the stock would be worth kr217.02 (4 258% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | kr4.98 |
0%
|
| Industry Average | 28.7 | kr217.02 |
+4 258%
|
| Country Average | 14.9 | kr112.44 |
+2 158%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
kr-23.4m
|
/ |
Jan 2026
kr-44.3m
|
= |
|
|
kr-23.4m
|
/ |
Dec 2026
kr-40.4m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
17.6m SEK | 0.7 | -0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.6B USD | 14.5 | 87.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD | 14.2 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.1B USD | 12.9 | 20.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.3B USD | 22.2 | 29.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 12.7 | 17.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.7B AUD | 11.2 | 33.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.5B EUR | 36 | 33.3 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.4 |
| Median | 14.9 |
| 70th Percentile | 19.4 |
| Max | 4 325.3 |
Other Multiples
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
